Acute Citrulline Malate Shows Promise for Male Sprinters Going for Gold

Why It Matters

The study provides early evidence that acute CM supplementation could give sprinters a marginal performance edge in repeat‑sprint scenarios, a valuable insight for athletes, coaches, and the sports‑nutrition market.

Key Takeaways

• 8 g citrulline malate taken acutely improved second 100 m sprint.
• Study involved 11 elite male collegiate sprinters in crossover design.
• Lactate rise higher with CM, indicating sustained glycolytic output.
• Athletes reported lower perceived fatigue after CM versus placebo.
• Mechanistic markers like nitric oxide were not measured, limiting conclusions.

Pulse Analysis

Citrulline malate (CM) has become a staple in the sports‑nutrition aisle, marketed for its ability to boost nitric‑oxide production, enhance blood flow, and blunt fatigue. While most peer‑reviewed work has focused on endurance cyclists or strength athletes, the compound’s rapid‑energy demands of a 100‑meter dash have received little attention. Theoretically, CM could accelerate the clearance of ammonia and support the ATP‑phosphocreatine system, offering a marginal edge in events where hundredths of a second decide podium positions.

The Japanese crossover trial enrolled eleven male collegiate sprinters, each completing two maximal 100‑meter sprints under blinded conditions with either an 8‑gram acute dose of CM or a placebo. Timing gates and high‑speed video confirmed that the first sprint was identical across treatments, but the second sprint was modestly faster after CM ingestion. Blood lactate rose more sharply in the CM condition, suggesting athletes could sustain a higher glycolytic contribution, while subjective ratings indicated reduced perceived exertion. These physiological signals align with the hypothesized nitric‑oxide‑mediated improvements, though direct markers were not measured.

From a business perspective, the findings give supplement manufacturers a data point to justify acute CM products aimed at track athletes, a niche yet growing market segment. However, the modest performance gain and the study’s small sample size temper expectations; regulators and coaches will likely demand larger, multi‑event trials before endorsing routine use. For athletes, the takeaway is that a single 8‑gram dose may shave fractions of a second off repeat sprints, but long‑term safety and efficacy remain unproven. Ongoing research will determine whether CM can transition from a trendy ergogenic aid to a validated sprint‑performance tool.